$ACXP In December 2014, Merck ($MRK) paid US$9.5 billion for Cubist ($CBST) largely to obtain marketing access to agents daptomycin and fidaxomicin. Acurx finds itself in an eerily analogous situation, with an agent for MRSA and VRE, as well as another for C. diff. With its lead agent about to advance to phase 2b, perhaps US$100 million is a fair pre-market valuation for Acurx, which tentatively plans IPO in mid-2021. Success with both agents could thus poise pre-market Acurx investors for plausible gains of perhaps 250-500 percent
2
2 Likes